Moody's Sees Merck's (MRK) Divestiture Plans as Credit-Negative Event

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/25/2026

1. AKAM
2. COST
3. SPY
4. ZS
5. META
6. NVDA
7. DRI
8. ULS
9. CRL
10. VEON

Go back to Moody's Sees Merck's (MRK) Divestiture Plans as Credit-Negative Event

Alnylam Pharmaceuticals (ALNY) Surges on Deal to Acquire Merck's (MRK) Sirna Therapeutics for $175M+

January 13, 2014 9:24 AM EST

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is surging 29% in pre-open trade in part after announcing late Sunday the acquisition of Merck's (NYSE: MRK) wholly owned subsidiary Sirna Therapeutics, Inc. (Sirna Therapeutics), comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry,... More

Merck (MRK) Updates on Cost-Savings Goals; Plans Divestiture of Animal Health Business

January 13, 2014 8:37 AM EST

Merck (NYSE: MRK) will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value in non-core areas of its business. In October 2013, Merck announced a multi-year initiative to resource opportunities that offer the greatest potential return on investment, improve the companys performance in the short term and create long-term value.

Were taking significant and decisive action to make Merck a more competitive company, better positioned to drive innovation... More